论文部分内容阅读
目的探究葛根素注射液联合盐酸法舒地尔治疗缺血性脑梗死的临床疗效。方法选取2014年6月—2015年6月广州市花都区花山镇卫生院收治的缺血性脑梗死患者84例,按照治疗方法的不同分为对照组和治疗组,每组各42例。对照组静脉滴注盐酸法舒地尔注射液,60 mg加入到250 m L生理盐水中,1次/d。治疗组在对照组治疗的基础上静脉滴注葛根素注射液,400 mg加入生理盐水250 m L,1次/d。两组患者均连续治疗14 d。观察两组的临床疗效,同时比较两组治疗前后红细胞沉降率(ESR)、血细胞比容(HCT)、纤维蛋白原(FIB)、红细胞聚集指数(RF)、全血高切黏度(HS)、神经功能缺损(NIHSS)评分、血管内皮素-1(ET-1)的变化情况。比较两组不良反应发生情况。结果治疗后,对照组和治疗组的总有效率分别为80.95%、95.24%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组ESR、HCT、FIB、RF、HS、NIHSS评分、ET-1均较治疗前显著降低,同组治疗前后差异有统计学意义(P<0.05);且治疗组这些观察指标的降低程度优于对照组,两组比较差异有统计学意义(P<0.05)。对照组和治疗组的不良反应发生率分别为9.52%、7.14%;两组比较差异无统计学意义。结论葛根素注射液联合盐酸法舒地尔治疗缺血性脑梗死具有较好的临床疗效,能够明显改善患者的血液流变学状态,并能显著降低ET-1的表达,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy of puerarin combined with fasudil hydrochloride in the treatment of ischemic cerebral infarction. Methods From June 2014 to June 2015, 84 patients with ischemic cerebral infarction admitted from Huashan Town Hospital of Huadu District, Guangzhou City were divided into control group and treatment group with 42 cases in each group according to different treatment methods. Control group intravenous fasudil hydrochloride injection, 60 mg added to 250 m L normal saline, 1 / d. The treatment group in the control group based on the treatment of intravenous drip Puerarin injection, 400 mg saline 250 m L, 1 / d. Two groups of patients were treated for 14 days. The clinical effects of the two groups were observed. The ESR, HCT, FIB, HS, HS, Neurological deficit score (NIHSS), endothelin-1 (ET-1) changes. Adverse reactions between the two groups were compared. Results After treatment, the total effective rates of the control group and the treatment group were 80.95% and 95.24%, respectively. There was significant difference between the two groups (P <0.05). After treatment, the ESR, HCT, FIB, RF, HS, NIHSS score and ET-1 in the two groups were significantly lower than those before treatment, the difference was statistically significant before and after treatment (P <0.05) The degree of reduction was better than that of the control group, with significant difference between the two groups (P <0.05). The incidence of adverse reactions in the control group and the treatment group were 9.52% and 7.14% respectively. There was no significant difference between the two groups. Conclusion Puerarin injection combined with fasudil hydrochloride in the treatment of ischemic cerebral infarction has a good clinical efficacy, can significantly improve the patient’s hemorheological status, and can significantly reduce the expression of ET-1, has some clinical promotion Value.